AIM ImmunoTech (NYSE:AIM) versus Mesoblast (NASDAQ:MESO) Financial Survey

AIM ImmunoTech (NYSE:AIM) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares AIM ImmunoTech and Mesoblast’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AIM ImmunoTech	-12,594.21%	-421.73%	-147.54%
Mesoblast	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for AIM ImmunoTech and Mesoblast, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIM ImmunoTech	0	0	2	0	3.00
Mesoblast	0	1	3	0	2.75

AIM ImmunoTech presently has a consensus price target of $2.75, indicating a potential upside of 1,179.07%. Mesoblast has a consensus price target of $13.50, indicating a potential downside of 21.42%. Given AIM ImmunoTech’s stronger consensus rating and higher probable upside, equities research analysts plainly believe AIM ImmunoTech is more favorable than Mesoblast.

Earnings and Valuation

This table compares AIM ImmunoTech and Mesoblast”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIM ImmunoTech	$190,000.00	72.17	-$28.96 million	($0.47)	-0.46
Mesoblast	$5.90 million	333.83	-$87.96 million	N/A	N/A

AIM ImmunoTech has higher earnings, but lower revenue than Mesoblast.

Risk & Volatility

AIM ImmunoTech has a beta of -0.36, suggesting that its share price is 136% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.36, suggesting that its share price is 236% more volatile than the S&P 500.

Institutional & Insider Ownership

12.0% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Mesoblast beats AIM ImmunoTech on 8 of the 12 factors compared between the two stocks.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.